Search
Search Results
-
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
BackgroundInhibition of the adenosine 2A receptor (A 2A R) diminishes the immunosuppressive effects of adenosine and may complement immune-targeting...
-
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
PurposeImaradenant is a novel potent and selective adenosine A2A receptor antagonist that is hypothesized to reduce immune suppression in the tumor...
-
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity,...
-
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the...
-
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of...
-
Prostate Cancer Immunotherapy—Finally in From the Cold?
Purpose of ReviewDespite significant progress, patients with metastatic prostate cancer continue to have poor prognosis. Immunotherapy has...
-
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4...
-
The adenosine pathway in immuno-oncology
Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has revolutionized cancer care. Nevertheless, a large proportion...
-
Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade
BackgroundMethotrexate (MTX) is a common chemotherapeutic drug that inhibits DNA synthesis and induces apoptosis. Treatment with MTX increased CD73...
-
Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment
The development of new therapies based on tumor biology is one of the main topics in cancer treatment. In this regard, investigating the...
-
Myeloid-derived suppressor cells in cancer and cancer therapy
Anticancer agents continue to dominate the list of newly approved drugs, approximately half of which are immunotherapies. This trend illustrates the...
-
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Recent studies have demonstrated the potential of natural killer (NK) cells in immunotherapy to treat multiple types of cancer. NK cells are innate...
-
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy,...
-
Foundations of gastrointestinal-based drug delivery and future developments
Gastrointestinal-based drug delivery is considered the preferred mode of drug administration owing to its convenience for patients, which improves...
-
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved...
-
Novel Targets for the Treatment of Melanoma
Purpose of ReviewIn this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update...
-
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive...
-
Emerging immunological strategies: recent advances and future directions
Immunotherapy plays a compelling role in cancer treatment and has already made remarkable progress. However, many patients receiving immune...
-
Heterogeneity of the tumor immune microenvironment and clinical interventions
The tumor immune microenvironment (TIME) is broadly composed of various immune cells, and its heterogeneity is characterized by both immune cells and...
-
Targeting adenosine for cancer immunotherapy
Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have...
